You are here

Mushroom Extract May Eradicate Human Papilloma Virus in Women

Daily Use of AHCC Supplement Could Support Immune System, Eliminate HPV

A presentation at the October conference of the Society for Integrative Oncology in Scottsdale, Arizona, revealed that daily use of the AHCC supplement could support the host immune system to eradicate HPV infection in women.

Results from an ongoing clinical trial evaluating AHCC for the treatment of HPV indicated that close to 60 percent of the patients showed no signs of the infection at six months of treatment. The randomized, double-blind, placebo-controlled study is following 50 women for up to 12 months, with one group taking six 500-mg capsules of AHCC and a second group receiving placebo.

Currently, there is no standard of care for persistent, high-risk HPV infections. AHCC is a natural, immune-modulating compound derived from specially cultured medicinal mushroom roots. The supplement is well-tolerated in patients who receive it and studies indicate that it works by increasing the number and/or activity of natural killer (NK) cells, killer T-cells, dendritic cells, and cytokines. This enables the body to effectively fight infections.

Multiple studies have demonstrated that AHCC improves the quality of life of cancer patients. In addition, the supplement has been shown to reduce viral loads in patients with hepatitis C as well as helping patients with non-viral liver disease.

Source: BioSpace.com, November 5, 2018

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs